+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the safety of combining inavolisib and fulvestrant, with or without palbociclib, in adults who have PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer and type 2 diabetes. The study focuses on monitoring adverse effects, especially those related to blood sugar levels, in participants receiving this treatment combination. Participants will receive oral inavolisib on days 2 to 28 of each 28-day cycle. Intramuscular fulvestrant is given on days 1 and 15 during the first cycle, then on day 1 of each following cycle. Some participants will also take oral palbociclib on days 1 to 21 of each cycle. This is an open-label, single-group phase II study with treatment continuing up to approximately 21 months. During the study, participants will be regularly assessed for adverse events including severe hyperglycemia and hospitalizations related to high blood sugar. Researchers will also monitor treatment side effects, response rates, disease progression, overall survival, and quality of life using questionnaires and clinical evaluations. Laboratory tests and performance status will be checked to ensure safety, with the study lasting up to about 21 months per participant.

Age: 18Years +All GendersPhase 2
10 locations
G

Actively Recruiting

Researchers are investigating ASP2138, a drug designed to target the protein CLDN18.2 found on digestive system cells and some tumors. This study focuses on adults with HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction GEJ cancer that is locally advanced and cannot be removed by surgery or has spread to other parts of the body. The goal is to see if adding ASP2138 to standard chemotherapy and pembrolizumab helps control the cancer better than placebo with chemotherapy, with or without pembrolizumab. Participants will be randomly assigned to one of two groups. One group receives ASP2138 injections under the skin every two or three weeks along with chemotherapy drugs either CAPOX or mFOLFOX6 and pembrolizumab infusions. The other group receives matching placebo injections and infusions with chemotherapy, with or without pembrolizumab. Treatments continue in 42-day cycles until the cancer worsens, medical issues arise, or study rules require stopping. Treatment schedules vary slightly depending on the chemotherapy regimen. During the study, participants will have regular safety checks and tumor scans until their cancer progresses. Researchers will monitor overall survival and progression-free survival up to 54 months. Additional measures include response rates, disease control, duration of response, quality of life assessments, adverse events, and laboratory tests. The study includes detailed monitoring of immune responses and drug levels, with the total participation lasting until disease progression or other stopping criteria are met.

Age: 18Years +All GendersPhase 3
8 locations
R

Actively Recruiting

Researchers are evaluating clazakizumab, a drug administered by subcutaneous injection, to study its effect on reducing high-sensitivity C-reactive protein hsCRP, a marker of inflammation, in adults with elevated hsCRP and increased risk for cardiovascular events. This phase 2b, randomized, double-blind, placebo-controlled study focuses on adults with established atherosclerotic cardiovascular disease or other risk factors such as obesity, type 2 diabetes, hypertension, or chronic kidney disease. The study aims to understand how clazakizumab compares to placebo in lowering inflammation related to cardiovascular risk. Participants will receive one of several doses of clazakizumab or a placebo via subcutaneous injection. The treatment period involves dosing and monitoring up to 32 weeks, with the primary outcome measured at 12 weeks and additional assessments at 24 weeks. The study includes a double-blind design where neither participants nor researchers know who receives the active drug or placebo. Pharmacokinetics of clazakizumab will also be evaluated during the trial. Throughout the approximately 9-month participation, participants will undergo blood tests to measure hsCRP levels at baseline and multiple follow-up points, including week 12 and week 24. Researchers will assess the percent change in hsCRP to evaluate inflammation changes. Safety and drug concentration will be monitored regularly. Participants will have scheduled visits for study drug administration and assessments, ensuring careful observation during the study period.

Age: 18Years +All GendersPhase 2
46 locations
P

Actively Recruiting

Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.

Age: 18Years +All GendersPhase 3
143 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of eloralintide in adults who are obese or overweight but do not have type 2 diabetes. This Phase 3 clinical trial aims to understand how eloralintide affects body weight and other health measures over time in this population. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all given by subcutaneous injection. The main phase of the study lasts about 75 weeks, and participants with prediabetes may continue into an extension phase for an additional 2 years to further assess long-term effects. During the study, participants will have regular visits for assessments including body weight, body fat, waist circumference, blood pressure, blood tests, and questionnaires on overall health. Researchers will monitor changes from baseline up to week 64 and longer for some measures, including the time to develop type 2 diabetes. Safety and medication use will also be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
158 locations
E

Actively Recruiting

Researchers are studying risankizumab, a drug approved for adults with certain conditions, to evaluate its effects in children aged 2 to under 18 years with moderately to severely active Crohns Disease who have not responded well or are intolerant to other treatments. This Phase 3 study includes three groups by age and involves multiple study parts to assess how the drug moves through the body, its safety, and its impact on disease activity. Participants will receive risankizumab through an intravenous infusion during a 12-week induction phase. Those who complete this phase may enter a 52-week maintenance period where they receive one of two doses of the drug by subcutaneous injection without knowing which dose they get. Afterward, participants can join a 208-week open-label extension phase with risankizumab dosing based on their previous response. During the study, participants will attend regular visits at hospitals or clinics where medical assessments, blood tests, and questionnaires will be used to monitor disease activity and check for side effects. Key measures include clinical remission and endoscopic response at 12 and 64 weeks. Follow-up continues for about 140 days after treatment periods, allowing researchers to understand the drugs effects and safety over time.

Age: 2Years - 17YearsAll GendersPhase 3
85 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.

Age: 6Years - 17YearsAll GendersPhase 3
98 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of standard chemotherapy with or without the drug INCB161734 in people with metastatic pancreatic ductal adenocarcinoma PDAC that has a specific KRAS G12D mutation. This is a Phase 3 randomized, double-blind trial aiming to compare these treatments in patients who have not received prior systemic treatment for their metastatic cancer. Participants will receive either oral INCB161734 tablets or placebo tablets alongside chemotherapy chosen by the investigator, either mFOLFIRINOX or GemNabP, as per the study protocol. The study compares these two groups to assess outcomes such as survival and response to treatment. Treatment and observation will continue for up to approximately two to three years depending on the outcome being measured. During the trial, participants will undergo regular assessments including survival monitoring, tumor response evaluations by blinded independent central review and investigator assessments, and quality of life questionnaires. Researchers will also monitor adverse events and organ function. The study involves scheduled visits and tests over the course of treatment and follow-up lasting up to several years to understand long-term effects and treatment impact.

Age: 18Years +All GendersPhase 3
230 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of standard chemotherapy combined with bevacizumab, with or without the addition of INCA33890, for the first-line treatment of adults with metastatic microsatellite stable colorectal cancer who have not received prior systemic treatment for metastatic disease. This phase 3 randomized, double-blind study aims to compare these treatment approaches to better understand their impact on disease progression. Participants will receive either INCA33890 or a placebo in combination with bevacizumab and FOLFOX chemotherapy at doses defined by the study protocol. The treatments are given as part of a randomized, parallel group design where neither the participants nor the investigators know which treatment is assigned. This study will assess outcomes over several years, with primary evaluation focused on progression-free survival for up to 3 years. Throughout the study, participants will be monitored regularly for treatment response, survival, and safety through various assessments including laboratory tests and quality of life questionnaires. Researchers will measure overall survival, objective response rate, duration of response, and treatment-related adverse events for up to 4 years. Quality of life changes will also be tracked using validated questionnaires. The total duration of participation may extend up to around 4 years, with ongoing safety and efficacy evaluations.

Age: 18Years +All GendersPhase 3
297 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.

Age: 18Years +All GendersPhase 2Phase 3
230 locations

1-10 of 23

1